Introduction
Arterial hypertension is one of the most important cardiovascular risk factors. 1 Blood pressure-lowering therapy has been shown to reduce substantially the burden of cardiovascular disease. 2, 3 Contemporary management of patients with hypertension includes the determination of global cardiovascular risk. Several methods have been developed to estimate 10-year risk of fatal or total cardiovascular disease. [4] [5] [6] The guidelines of the European Society of Hypertension for the management of hypertension also suggest a model for total cardiovascular risk prediction. 7, 8 The 2003 version contains several important modifications compared to the 1999 version. For example, diabetes has been included as an equivalent of target organ damage, to highlight its importance in cardiovascular disease. Based on several studies, echocardiography received a more important role, [9] [10] [11] [12] and left ventricular hypertrophy was clearly defined. However, the impact of echocardiographic left ventricular hypertrophy using the 2003 guidelines has been assessed in only one study. 13 Based on several studies showing an independent association of elevated high-sensitivity C-reactive protein (hsCRP) concentrations and cardiovascular events, 14, 15 an hsCRP concentration above 10 mg/l has been added as an individual risk factor. However, the contribution of a greatly increased hsCRP to individual risk stratification as proposed by the 2003 guidelines has not been examined. Furthermore, it is unclear whether applying a different cutoff level of 3 mg/l as suggested recently by Pearson et al. 16 would alter risk stratification. Therefore, the aim of the present study was to assess the contribution of echocardiographic left ventricular hypertrophy and two different hsCRP cutoff levels to risk stratification in an unselected sample of patients with arterial hypertension.
Materials and methods

Study population
The study population consisted of consecutive patients who attended the Outpatient Department of General Internal Medicine of the University Hospital Basel, Switzerland. Patients were included in the study if the average of two blood pressure readings on initial screening visit was X140 mm Hg for systolic blood pressure and/or 90 mm Hg for diastolic blood pressure. Elevated blood pressure had to be confirmed on another visit. Patients taking blood pressure-lowering therapy were excluded. Further exclusion criteria were a previous diagnosis of myocardial infarction, stroke, cardiac valve disease or heart failure, severe renal insufficiency (creatinine 4177 mmol/l (2 mg/dl)) or any other severe concomitant illness. Blood pressure was measured in a quiet environment and in a sitting position after at least 5 min of rest, using a standard mercury sphygmomanometer. The following parameters were assessed: clinical history, physical examination, routine laboratory profile including hsCRP, standard 12-lead electrocardiography (ECG) and echocardiography. The study was approved by the local ethics committee. Written informed consent was obtained from all subjects.
Laboratory analysis
Non-fasting venous blood samples were collected in ethylenediaminetetraacetic acid-containing tubes and processed immediately. Creatinine and lipid levels were measured according to standard methods. hsCRP concentrations were measured by immunonephelometry using a validated assay (DadeBehring, Liederbach, Germany). Urinary creatinine and albumin excretion were assessed in a clean midstream sample. Confounding urinary protein excretion was excluded before analysis by standard dipstick testing. Urinary creatinine was measured by standard enzymatic methods. Urinary albumin excretion was quantified using a nephelometric method.
Echocardiography
Echocardiography was performed using a Hewlett Packard 5500 system. Left ventricular diameters were obtained from parasternal views with optimal orientation to maximize left ventricular internal diameters as described previously. 17 Left ventricular mass was calculated according to the formula proposed by Devereux et al.: 18 left ventricular mass ¼ 0.8 Â (1.04 Â ((interventricular septal thickness þ posterior wall thickness þ end-diastolic diameter) 3 À(end-diastolic diameter) 3 )) þ 0.6. Left ventricular hypertrophy was defined as left ventricular mass index (left ventricular mass/body surface area) X125 g/m 2 for men and X110 g/m 2 for women as proposed by the European Society of Hypertension. 8 In 12 patients, standardized echocardiographic measurements were not feasible.
Risk stratification
Risk stratification was performed according to the 2003 guidelines for the management of arterial hypertension.
8 All patients were classified into four different risk categories according to the risk parameters described below: low added risk, moderate added risk, high added risk and very high added risk. 8 The first analysis was performed without including echocardiography and hsCRP values. Subsequently, echocardiography and/or hsCRP concentrations above 10 mg/l were added into the risk stratification process. Finally, an exploratory analysis using an hsCRP cutoff level of 3 mg/l was performed.
Office blood pressure levels were categorized into grade 1 hypertension (140-159 mm Hg for systolic or 90-99 mm Hg for diastolic blood pressure), grade 2 hypertension (160-179 mm Hg for systolic or 100-109 mm Hg for diastolic blood pressure) and grade 3 hypertension (4179 mm Hg for systolic or 4109 for diastolic blood pressure). The following risk factors for cardiovascular disease were considered: age 455 for men and 465 for women, current smoking, body mass index X30 kg/m 2 (waist circumference was not available), dyslipidaemia (any of the following: total cholesterol 46.5 mmol/l, low-density lipoprotein-cholesterol 44.0 mmol/l, high-density lipoprotein-cholesterol o1.0 mmol/l for men and o1.2 mmol/l for women or taking lipid-lowering treatment) and family history of premature cardiovascular disease. Family history was unknown or unavailable for 52 patients. Diabetes mellitus was defined as previous diagnosis of diabetes, concurrent treatment with insulin or oral antidiabetic drugs or non-fasting plasma glucose 411 mmol/l. A slight increase in serum creatinine was defined as a creatinine concentration between 115 and 133 mmol/l in men and between 107 and 124 mmol/l in women. Renal impairment was defined as a serum creatinine concentration 4133 mmol/l in men and 4124 mmol/l in women. Left ventricular hypertrophy on ECG was defined as Sokolow-Lyon index 438 mm or Cornell Voltage product 42440 mm ms. 8 Patients were classified as having microalbuminuria if albumin excretion was between 2.5 and 30 mg/mmol in men and 3.5 and 30 mg/mmol in women. Patients with urinary albumin excretion above 30 mg/mmol were classified as having proteinuria. 
Statistical analysis
Results
In total, 359 consecutive patients had confirmed blood pressure values of at least 140/90 mm Hg. Of these, 142 patients (40%) had treated hypertension and 10 patients (3%) had missing echocardiography and/or hsCRP concentrations, leaving 207 patients (58%) finally included in the study. Baseline characteristics are shown in Table 1 . Mean age was 55713 years and 56% of the patients were male. Using only personal history (including diabetes) and clinical examination for risk stratification in our patient cohort, 8% were in the low added risk group, 64% in the moderate added risk group, 16% in the high added risk group and 12% in the very high added risk group. After adding target organ damage on ECG and/or laboratory analyses (including urinary albumin excretion) but not echocardiography or hsCRP, 36 additional patients (17%) were classified as being at high or very high added risk instead of being at low or moderate added risk.
Cardiac mass index was significantly different between the four risk stratification groups (P ¼ 0.001), being higher in patients at higher risk. Nevertheless, adding echocardiography to risk stratification changed only very little in the distribution of patients (Table 2 ). hsCRP concentrations were significantly different between patients in the four different risk groups (P ¼ 0.014). Again, patients at higher cardiovascular risk had higher hsCRP levels. However, adding hsCRP concentrations above 10 mg/l did not influence the risk stratification process.
The different models of risk stratification and the influence of increased hsCRP levels and echocardiography on risk stratification are shown in detail in Table 2 . Most patients were at moderate or high cardiovascular risk before including hsCRP or echocardiography into the model. Including echocardiographic left ventricular hypertrophy in the risk stratification process had minimal impact. Only three patients (1.4%) were reclassified in the high added risk instead of the moderate added risk group. All other patients remained in the same category. As noted above, hsCRP concentration above 10 mg/l had no impact on risk stratification. Using an hsCRP cutoff level of 3 mg/l for risk stratification, more patients (5%) had to be reclassified (Table 2) . Applying the same risk stratification process to patients with treated hypertension revealed very similar results (data not shown).
Discussion
The present study revealed that in outpatients with arterial hypertension echocardiography and hsCRP at the currently recommended cutoff level of 10 mg/l have a minimal impact on risk stratification according to the current guidelines for the management of hypertension. 8 No patient had to be reclassified because of increased hsCRP concentrations. When echocardiographic left ventricular hypertrophy was added for risk stratification, only three patients (1%) had to be reclassified from the moderate to the high added risk group. Using an hsCRP cutoff of 3 mg/l, a higher proportion of patients (5%) changed the risk category, but still only a minority of patients had to be reclassified.
hsCRP concentrations have no impact on risk stratification when the proposed cutoff level of 10 mg/l is used. 8 As the prevalence of very high hsCRP levels is low, 19 the impact on risk stratification may be low as well. Furthermore, hsCRP concentrations are correlated to urinary albumin excretion. 20 This may have lowered the impact of elevated hsCRP on risk stratification. However, our study shows that a lower hsCRP cutoff level of 3 mg/l, as proposed recently by the American Heart Association, 16 may lead to greater changes in risk stratification. Further studies are necessary to evaluate whether a cutoff level of 3 mg/l effectively identifies patients at increased cardiovascular risk within this specific risk stratification process. The definite value of hsCRP in cardiovascular risk prediction in this setting remains unclear. Increased hsCRP concentrations may identify high-risk patients who benefit from specific therapy.
14 On the other hand, low hsCRP concentrations may be useful for risk stratification as well. 21, 22 For example, we previously showed that a combination of low hsCRP and low B-type natriuretic peptide concentrations is useful to exclude echocardiographic left ventricular hypertrophy in patients with hypertension. 22 Our results contradict several previous reports about the value of adding echocardiography to risk stratification. [9] [10] [11] [12] All these studies showed a substantial impact of echocardiography on risk stratification in patients with untreated hypertension. Several factors may be responsible for these striking differences compared to the present study. Importantly, all previous studies used the 1999 guidelines for the management of arterial hypertension. 7 Our study is one of the first applying the 2003 guidelines. Based on recent trial data, several important changes have been performed in the 2003 guidelines: diabetes has been reclassified as an equivalent to target organ damage and creatinine concentrations for associated clinical conditions have been lowered from 2.0 mg/dl (177 mmol/l) to 1.5 mg/dl (133 mmol/l). Importantly, microalbuminuria has been introduced as a target organ damage independent of diabetes. All these factors may have contributed to the hypothesis that echocardiographic left ventricular hypertrophy has a much smaller impact on risk stratification according to the 2003 guidelines. 7, 8 Microalbuminuria has been shown to be correlated with left ventricular mass, 12, 23, 24 and might therefore have lowered the independent value of echocardiography to detect target organ damage. These findings may also be seen as an indirect confirmation of the integrative role of microalbuminuria in the development and progression of cardiovascular disease in hypertensive patients. 25 As the determination of microalbuminuria is easy, inexpensive and widely available, it is preferable to measure urinary albumin excretion before quantifying left ventricular mass on echocardiography. The only study we found about risk stratification in patients with hypertension using the 2003 guidelines found a somewhat more important role of echocardiography. 13 Differences in the determination of urinary albumin excretion (strips versus nephelometry), in the definition of left ventricular hypertrophy on ECG (adding Cornell Voltage product in our study) and in the prevalence of left ventricular hypertrophy on echocardiography are reasonable explanations for these discrepant findings.
The relatively low prevalence of left ventricular hypertrophy on echocardiography may have contributed to the low impact of left ventricular hypertrophy on risk stratification. It is difficult to explain the substantial differences in the prevalence of left ventricular hypertrophy between different studies. [9] [10] [11] [12] [13] Patient selection from a hypertension clinic in previous studies compared to a general medical outpatient clinic in the present study may be partially responsible. However, the prevalence of echocardiographic left ventricular hypertrophy in the present study is consistent with that recently reported in a general population sample. 26 The major impact of adding hsCRP levels 3 mg/l or echocardiography to risk stratification was seen in the moderate and high added risk group. These findings show that new risk stratification tools are most helpful in these intermediate risk groups, because low-risk patients are likely to remain at low risk despite adding new risk stratification tests, and those in the very high added risk group already are at high cardiovascular risk.
This study has limitations. Firstly, a cross-sectional analysis was performed. Therefore, no information can be provided about the real outcome of the patients included in the study. Secondly, the vast majority of our patients were white subjects and our findings may not be generalizable to non-white subjects. As, among different ethnicities, there are substantial differences in hsCRP levels 27, 28 and in the relationship of hsCRP levels to hypertension, 29 the value of increased hsCRP levels in risk stratification may also vary between different ethnicities. Ethnic differences in risk stratification may further be present owing to differences in the prevalence of left ventricular hypertrophy. 30, 31 Thirdly, although we did a comprehensive risk stratification in our patients, some risk markers were not completely assessed (e.g. family history was available only for 155 patients). However, if more information had been available, echocardiography and hsCRP concentrations would have had even less impact on risk Risk stratification in hypertension D Conen et al stratification. Finally, a significant effect of hsCRP on risk stratification in a substantially larger, population-based sample cannot be excluded.
In conclusion, using the 2003 guidelines for the management of arterial hypertension, hsCRP at the proposed cutoff level of 10 mg/l has no impact on risk stratification in outpatients with hypertension. Furthermore, the results of the present study suggest that echocardiography may not be necessary for risk stratification in all patients with arterial hypertension. hsCRP concentrations currently should not be routinely measured for risk stratification of hypertensive individuals. However, an hsCRP cutoff level of 3 mg/l may be more suitable for risk stratification in patients with hypertension.
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